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Background/aim
This post-hoc analysis examined the efficacy and safety
of twice-daily insulin lispro low mixture (LM25) and
once-daily basal insulin glargine plus once-daily prandial
insulin lispro (IGL) in a Latin American subpopulation
(Argentina, Brazil, and Mexico) of participants with type
2 diabetes mellitus (T2D).
Materials and methods
This phase 4, randomized, open-label, parallel-arm trial
included participants aged 18–75 yrs. with T2D who
were taking once-daily insulin glargine and stable doses
of metformin and/or pioglitazone and had glycosylated
hemoglobin (HbA1c) between ≥7.5% and ≤10.5% and
fasting plasma glucose ≤6.7 mmol/L (121 mg/dL). Partici-
pants were randomized 1: 1 to receive twice-daily LM25
(before breakfast and dinner) or basal insulin glargine (at
bedtime) and IGL (before the largest daily meal) in addi-
tion to their existing dose of metformin and/or pioglita-
zone for 24 weeks. The primary efficacy outcome was the
change in HbA1c from baseline to Week 24.
Results
A total of 162 participants (80 LM25; 82 IGL) with a
mean (standard deviation [SD]) age of 57.3 (9.0) yrs. and
body mass index of 31.3 (5.2) kg/m2 were included. The
mean (SD) change in HbA1c (%) from baseline was -1.5
(1.0) in the LM25 group and -1.0 (1.2) in the IGL group
(Figure 1). At Week 24, 35.1% of participants in the
LM25 group and 31.6% of participants in the IGL group
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Figure 1 Observed HbA1c levels at Baseline, Week 12, and Week 24
in patients receiving insulin lispro low mixture (LM25; 75% insulin
lispro protamine suspension and 25% insulin lispro solution 25%)
twice daily or basal insulin glargine once daily and prandial insulin
lispro once daily (IGL). Abbreviation: HbA1c=glycosylated
hemoglobin.




© 2015 Barbieri et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
achieved the target HbA1c <7.0%. Fasting blood glucose
and glycemic variability at Week 24 were similar
between the 2 groups, as was the mean (SD) total daily
insulin dose (LM25=61.0 [27.6] IU; IGL=60.6 [24.3] IU).
The mean (SD) rate of total hypoglycemia per 30 days
was numerically similar between the two groups
(LM25=1.6 [2.2]; IGL=1.8 [2.6] [overall study period]).
Mean (SD) weight gain from baseline to Week 24 was
2.4 (2.9) kg in the LM25 group and 1.0 (3.1) kg in the
IGL group. Treatment-emergent adverse events were
similar between the 2 groups.
Conclusions
The results of this post-hoc analysis in a Latin American
population are consistent with the results reported in
the trial-level population and suggest that both LM25
and IGL are viable treatment options for insulin intensi-
fication in patients with T2D who do not achieve glyce-
mic control on basal insulin glargine. ClinicalTrials.gov
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